Akebia Therapeutics tumbles after FDA setback on anemia drug trial

Akebia Therapeutics

28/10/2025 21:16

** Shares of drug developer Akebia Therapeutics AKBA.O fall 29% to $2.17 in extended trading

** Co says it will not pursue a broader U.S. label for its anemia drug, Vafseo

** Akebia failed to reach agreement with the U.S. FDA on the design of a planned trial for chronic kidney disease patients not on dialysis

** FDA feedback suggested the trial would need far more patients, making it too costly and time-consuming - AKBA

** Vafseo was approved by the FDA in 2024 for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months

** Stock up 62% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))